Methyl 2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: Methyl 2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate
• 化学式: C₂₂H₁₈O₉
• 分子量: 426.4
• InChiKey: FCUPTGDGQULLKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  158
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  Methyl 2-ethyl-2,5,7,12-tetrahydroxy-4,6,11-trioxo-1,3-dihydrotetracene-1-carboxylate 、 对甲苯磺酸 以 苯 为溶剂， 反应 4.0h， 以anhydromaggiemycin, at a yield of 84%, was obtained的产率得到苯磺酰胺,2-[2-(4-羟基-8-甲氧基-1-萘基)二氮烯基]-5-硝基-,离子(1-)
  参考文献：
  名称：

  Maggiemycin, anhydromaggiemycin and processes for making

  摘要：

  新的蒽环类抗生素被制备出来，包括马吉霉素、无水马吉霉素和7-氧化多柔比星酮。马吉霉素、无水马吉霉素和7-氧化多柔比星酮均表现出生物活性，对KB、L1210和P388细胞系有毒性。

  公开号：

  US04501699A1

文献信息

• COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS
  申请人：Biotie Therapies Corp.

  公开号：EP1931706A1

  公开（公告）日：2008-06-18
• EP1931706A4
  申请人：——

  公开号：EP1931706A4

  公开（公告）日：2009-05-27
• Collagen Receptor I-Domain Binding Modulators
  申请人：Heino Jyrki

  公开号：US20080255028A1

  公开（公告）日：2008-10-16

  The present invention relates to a refined and detailed molecular model of the α2⊕1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially α2β1 integrin modulators. The present invention further relates to novel α2β1 I-domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides. The present invention further relates to the use of such modulators for the manufacture of medicaments for thrombosis, inflammation and/or cancer
• [EN] COLLAGEN RECEPTOR I-DOMAIN BINDING MODULATORS<br/>[FR] MODULATEURS SE LIANT À UN DOMAINE L DES RÉCEPTEURS DU COLLAGÈNE
  申请人：BIOTIE THERAPIES CORP

  公开号：WO2007031608A1

  公开（公告）日：2007-03-22

  [EN] The present invention relates to a refined and detailed molecular model of the a2ß1 integrin l-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially a2ß1 integrin modulators. The present invention further relates to novel a2ß1 I- domain modulators, which are of therapeutic potential. The present invention further relates to specific families of small molecule modulators interacting with collagen receptors, tetracyclic polyketides and sulfonamides. The present invention further relates to the use of such modulators for the manufacture of medicaments for thrombosis, inflammation and/or cancer.
  [FR] La présent invention concerne un modèle moléculaire perfectionné et détaillé du domaine l de l'intégrine a2ß1, en particulier le MIDAS, ainsi que l'utilisation d'un tel modèle pour la conception de nouveaux modulateurs de l'intégrine, en particulier les modulateurs de l'intégrine a2ß1. Cette invention concerne également de nouveaux modulateurs du domaine I de a2ß1 qui présentent un potentiel thérapeutique. Cette invention concerne également des familles spécifiques de modulateurs de petites molécules qui interagissent avec les récepteurs du collagène, les polykétides tétracycliques et les sulfamides. L'invention concerne également l'utilisation de ces modulateurs en vue de fabriquer des médicaments pour la thrombose, l'inflammation et/ou le cancer.
• Maggiemycin, anhydromaggiemycin and processes for making
  申请人：Litton Bionetics, Inc.

  公开号：US04501699A1

  公开（公告）日：1985-02-26

  New anthracyclinones, including maggiemycin, anhydromaggiemycin and 7-oxidodaunorubicinone, have been prepared. Maggiemycin, anhydromaggiemycin, and 7-oxidodaunorubicinone all exhibit biological activity; they are toxic to cell lines KB, L1210 and P388.

  新的蒽环类抗生素被制备出来，包括马吉霉素、无水马吉霉素和7-氧化多柔比星酮。马吉霉素、无水马吉霉素和7-氧化多柔比星酮均表现出生物活性，对KB、L1210和P388细胞系有毒性。